Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions

WEDNESDAY, Sept. 25, 2019 -- In moderate-to-severe ulcerative colitis, vedolizumab is superior to adalimumab for achieving clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission, and ustekinumab is superior to...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news